Emerging probiotics: future therapeutics for human gut health

新兴益生菌:未来人类肠道健康的治疗方法

阅读:2

Abstract

The microbial communities that colonize the human large intestine can influence many aspects of health and Bacillota strains, in particular, have been proposed as next-generation probiotics. Of note are strains including fibre-degraders, butyrate producers, lactate producers and utilizers, and other beneficial metabolic activities that are important for health. To illustrate the potential applications of colonic bacteria to design novel prebiotic formulations, a comparative genomics analysis of 16 bacterial strains isolated from the human gut was performed. This analysis revealed a high number of carbohydrate-active enzymes (CAZymes) in the genome sequences of understudied Lachnospiraceae and Oscillospiraceae members including Roseburia intestinalis L1-82, Roseburia faecis M72/1, Butyrivibrio fibrisolvens 16-4, and Ruminococcus bicirculans 80/3, ranging from 32 to 56 CAZymes across different strains. These strains showed complementary enzymatic profiles covering a wide range of different activities required to degrade prebiotic substrates derived from vegetable sources such as arabino- and xylo-oligosaccharides and pectic-oligosaccharides. These metabolic differences highlight the potential of these strains to cross feed and to allow the design novel probiotic consortia for microbiota-oriented interventions that could target specific disease conditions. These bacterial strains are, however, strict anaerobes and therefore special measures may need to be put in place to overcome these limitations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。